Relay Therapeutics RLAY 深 沪
等待开盘 07-17 09:30:00 美东时间
3.64
+0.140
+4.00%
华盛通- 最 高3.82
- 今 开3.55
- 成交量 426.37万股
- 最 低 3.5218
- 昨 收 3.50
- 总市值 6.22亿
- 52周最高 10.72
- 市盈率 静 --
- 换手率 2.49%
- 52周最低 1.775
- 委 比 57.50%
- 总股本 1.71亿
- 历史最高 64.37
- 量 比 2.90
- 振 幅 8.52%
- 历史最低 1.775
- 每 手 1
- 风险率 1.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多reAlpha Enhances Mortgage Operations with AI-Powered Loan Officer Assistant
<p>reAlpha Tech Corp. 推出了AI-powered Internal Loan Officer Assistant，旨在提升抵押贷款处理的效率和准确性。该工具已将手动文档准备时间减少60%，并自动化了三分之一的贷款申请流程。公司CEO Jamie Cavanaugh表示，AI工具不是替代人员，而是帮助专业人士更专注于客户服务。行业数据显示，AI技术可将贷款产量提升50%，缩短审批时间，并降低成本30-50%。reAlpha计划继续扩展AI工具以处理更复杂的抵押贷款场景。</p>
07-02 22:00
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
Relay Therapeutics announced the appointment of Dr. Claire Mazumdar to its Board of Directors. Dr. Mazumdar, a seasoned executive with expertise in clinical-stage oncology, joins as Relay prepares to initiate its Phase 3 ReDiscover-2 breast cancer trial. Previously, she was CEO of Bicara Therapeutics and held leadership roles at Rheos Medicines and Third Rock Ventures. Relay Therapeutics specializes in precision medicine, leveraging advanced comp...
06-11 20:05
Relay Therapeutics Announces Lease Termination Agreement
An announcement from Relay Therapeutics ( ($RLAY) ) is now available. On June 3...
06-05 04:56
高盛更新ASCO最新临床进展 三家美股药企获“买入”评级
高盛于6月2日发布研报，更新了其在美国临床肿瘤学会(ASCO)年会上所获取的相关信息，包括安进、再生元制药、Relay等制药公司旗下药物/疗法在临床试验方面的进展。
06-04 14:51
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
Relay Therapeutics announced updated interim data for RLY-2608, showing a median PFS of 11.0 months in second-line PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients. The data support the planned initiation of a Phase 3 trial, ReDiscover-2, in mid-2025. RLY-2608 demonstrated a promising efficacy profile and a well-tolerated safety profile. The company is also progressing next-generation triplet combinations with CDK4-selective inhibitors....
06-02 11:00
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Relay Therapeutics, Inc. announced that its management will participate in two upcoming fireside chats at the Jefferies Global Healthcare Conference on June 4, 2025, and the Goldman Sachs Global Healthcare Conference on June 11, 2025. Both events will be live webcast and available on Relay Therapeutics’ website under the News & Events section, with an archive available for 30 days. The company focuses on precision medicine by integrating advanced...
05-29 20:05
Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 27, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial intelligence is rapidly bec...
05-27 21:45
美股大行评级 | 潜在涨幅105.34%！Amylyx Pharmaceuticals获Leerink Partners升目标价至10美元，上调至"跑赢大市"评级
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
05-08 08:45
Guggenheim Maintains Buy on Relay Therapeutics, Lowers Price Target to $10
Guggenheim analyst Michael Schmidt maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price target from $30 to $10.
05-07 23:16
